
Kenneth Kun-Yu Wu, M. D., Ph.D.

NHRI/Academia Sinica

Phone No.: 037-206-166 ext. 38319

Fax No.: 037-586401

E-mail: kkgo@nhri.org.twWeb: <https://cs.nhri.org.tw/tw/honorary-investigators/>



Dr. Wu is a physician-scientist with a distinguished career in academic medicine. He was a chaired professor at University of Texas Medical School in Houston and MD Anderson Cancer Center and led the Division of Hematology for more than 20 years (1983-2006). He served on the US NIH hematology study section, NHLBI and NINDS program project review committees and was elected to serve on the NHLBI Advisory Council. He was a board member of the American Board of Internal Medicine (ABIM) and chaired the ABIM Hematology Subspecialty board.

He returned to Taiwan to work as Distinguished Fellow and Director of Institute of Biomedical Sciences (IBMS), Academia Sinica (1997-1999) and Distinguished Investigator and President, National Health Research Institutes (NHRI) (2006-2012). During his tenure in Taiwan, he served on a number of university, governmental and scientific society committees and currently is a member of Academia Sinica Council and Chair of the extramural scientific council of NHRI.

Dr. Wu's research activities cover two major areas. One area is clinical and epidemiological investigations of platelet function and cardiovascular diseases. He and his mentor John Hoak were the first to demonstrate a close relationship between platelet aggregation and myocardial infarction and stroke. He pioneered a clinical study to demonstrate the effect of aspirin on arterial thrombosis. He was a key member of the Atherosclerosis Risks in Communities (ARIC) study and made significant contributions in uncovering the role of hemostatic factors in atherosclerosis and thrombosis. Another area of research is biochemical and molecular biological investigations of cyclooxygenases (COX) and arachidonate metabolism. His laboratory proposed the existence of an inducible COX and characterized the transcriptional mechanism of COX-2. He and his co-workers pioneered the use of comparative metabolomics to identify 5-methoxytryptophan (5-MTP) as a COX-2 suppressing factor and use of biochemical and molecular biological approaches to characterize the biological activities of 5-MTP and its pathophysiological roles.

Dr. Wu's research accomplishments are recognized internationally. His published work is highly cited and continues to make contributions in his area of research. He was elected to distinguished scientific societies and is an academician of Academia Sinica. He received awards including Sanofi Prize from International Society of Thrombosis and Hemostasis and Presidential Science Prize of Taiwan.